With the previous top-selling biologic, Humira (adalimumab), now facing widespread biosimilar competition, one of the next major brand targets on the horizon has notched up impressive sales in its final year before biosimilar competition starts to bite.
Stelara (ustekinumab) brought in $10.858bn for Johnson & Johnson in 2023, according to the latest figures reported by the originator, with this total up 11.7% over 2022’s $9.723bn. In the US, sales grew by 9% to $6